Impact of Biosimilars on Oncology

Video

Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Caregiver & Housing Hurdles: Equity in HCT & CAR T Treatment
Caregiver & Housing Hurdles: Equity in HCT & CAR T Treatment
HCT & CAR T Access: Unseen Barriers & Inequities in Care
HCT & CAR T Access: Unseen Barriers & Inequities in Care
Understanding Why Darolutamide Stands Out Among ARPIs for mHSPC
Understanding Why Darolutamide Stands Out Among ARPIs for mHSPC
Weiss on How Nanoparticles are Enhancing Radiation Therapy in Lung Cancer
Weiss on How Nanoparticles are Enhancing Radiation Therapy in Lung Cancer
Navigating the Complexities of Immunotherapy in ALL
Navigating the Complexities of Immunotherapy in ALL
First-Line CLL/SLL: Is Chemo-Free the Future?
First-Line CLL/SLL: Is Chemo-Free the Future?
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
Elmariah on the Evolving Role of Fedratinib
Elmariah on the Evolving Role of Fedratinib
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
Related Content
SUNLIGHT Trial Defines CRC in the Refractory Setting

SUNLIGHT Trial Defines CRC in the Refractory Setting

Tony Berberabe, MPH
April 24th 2025
Article

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer

Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer

Morgan Bayer
April 23rd 2025
Article

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

Jason M. Broderick
April 22nd 2025
Article

The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Read More

TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

Jordyn Sava
April 22nd 2025
Article

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with stage IV colorectal cancer.

Read More